Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.37 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL17595174 | 0.98 | TSHR (0.38) | TSHRSMN1; SMN2RAB9AALDH1A1ALOX12 | |
| Hydroxyamine SCHEMBL3213770 | 0.96 | TSHR (0.37) | TSHRSMN1; SMN2RAB9AALDH1A1ALOX12 | |
| Edetic Acid SCHEMBL7787575 | 0.84 | TDP1 (0.40) | TSHRSMN1; SMN2RAB9ALMNA | |
| SCHEMBL2352790 | 0.84 | TSHR (0.31) | TSHRSMN1; SMN2RAB9AALDH1A1MEN1 | |
| SCHEMBL4381249 | 0.82 | TSHR (0.38) | TSHRSMN1; SMN2RAB9AALDH1A1ALOX12 | |
| SCHEMBL2634577 | 0.81 | SMN1; SMN2 (0.40) | TSHRSMN1; SMN2ALDH1A1HPGDGAA | |
| SCHEMBL5088057 | 0.77 | TSHR (0.37) | TSHRSMN1; SMN2RAB9AALDH1A1ALOX12 | |
| SCHEMBL5091798 | 0.76 | TSHR (0.44) | TSHRSMN1; SMN2RAB9AALDH1A1ALOX12 | |
| SCHEMBL16438029 | 0.73 | TSHR (0.37) | TSHRSMN1; SMN2RAB9AALDH1A1ALOX12 | |
| SCHEMBL14769217 | 0.72 | TSHR (0.52) | TSHRSMN1; SMN2RAB9AALDH1A1ALOX12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 7246 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4747409-A2 | COLLECTION, ASSESSMENT AND EARLY DETECTION OF HUMAN LUNG CANCER BIOMARKERS IN EXHALED BREATH CONDENSATES OF MOUSE ANIMAL MODELS | Hackensack Meridian Health, Inc. (US) | 2026-05-27 | — | — | EP | claimed |
| CN-122075736-A | Tumor microenvironment responsive enzyme prodrug conversion nano-composite and preparation method thereof | — | 2026-05-26 | — | — | CN | claimed |
| EP-4735009-A1 | FERRITIN-GOLD NANOPARTICLE CONJUGATES FOR PHOTODYNAMIC CANCER THERAPY | Temple University Of The Commonwealth System Of Higher Education (US) | 2026-05-06 | — | — | EP | claimed |
| EP-4727596-A2 | ANTIBODY-DRUG CONJUGATES AND LINKERS AND METHODS OF USE THEREOF | Ohio State Innovation Foundation (US) | 2026-04-22 | — | — | EP | claimed |
| US-12605473-B2 | Methods for making radiolabeled anti-MET binding proteins | REGENERON PHARMACEUTICALS, INC. (US) | 2026-04-21 | — | — | US | claimed |
| US-20260035410-A1 | THERAPEUTIC PEPTIDES AND METHODS OF PEPTIDE DESIGN | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2026-02-05 | — | — | US | claimed |
| EP-4649966-A2 | RADIOLABELED ANTI-PD-L1 ANTIBODIES FOR IMMUNO-PET IMAGING | Regeneron Pharmaceuticals, Inc. (US) | 2025-11-19 | — | — | EP | claimed |
| CN-120028537-A | Preparation method of low background value kit | 宁波瑞源生物科技有限公司 | 2025-05-23 | — | — | CN | claimed |
| CN-119470882-B | Enzyme-labeled secondary antibody polymer for immunohistochemical staining | 百盛(广州)生物制品有限公司 | 2025-04-11 | — | — | CN | claimed |
| WO-2025040093-A1 | MOLECULAR PROBES TARGETING GPC3 AND USE THEREOF | 武汉睿迪辐生物科技有限公司 | 2025-02-27 | — | — | WO | claimed |
| WO-1994020523-A1 | TUMOR TARGETING WITH L-ENANTIOMERIC OLIGONUCLEOTIDE CONJUGATES OF IMMUNOREAGENTS AND OF CHELATED RADIONUCLIDES | THE WELLCOME FOUNDATION LIMITED (GB) | 1994-09-15 | — | — | WO | claimed |
| WO-1994016741-A1 | IMMUNOREACTIVE REAGENTS EMPLOYING HETERODIMERS | THE WELLCOME FOUNDATION LIMITED (GB) | 1994-08-04 | — | — | WO | claimed |
| WO-1994013327-A1 | IMMUNOREACTIVE REAGENTS EMPLOYING DIHYDROFOLATE REDUCTASE | THE WELLCOME FOUNDATION LIMITED (GB) | 1994-06-23 | — | — | WO | claimed |
| WO-1994012216-A1 | SEQUENTIAL TARGETING OF TUMOR SITES WITH OLIGONUCLEOTIDE CONJUGATES OF ANTIBODY AND COMPLEMENTARY OLIGONUCLEOTIDE CONJUGATES OF CHELATED RADIONUCLIDE | THE WELLCOME FOUNDATION LIMITED (GB) | 1994-06-09 | — | — | WO | claimed |
| EP-0595863-A1 | IMPLANT MATERIALS | BRITISH TECHNOLOGY GROUP LTD (GB) | 1994-05-11 | — | — | EP | claimed |
| EP-0366770-B1 | LIPOSOMES COUPLED TO HORMONES | VESTAR INC (US) | 1994-02-09 | — | — | EP | claimed |
| US-5258499-A | Liposome targeting using receptor specific ligands | VESTAR, INC. (US) | 1993-11-02 | — | — | US | claimed |
| WO-1993000935-A1 | IMPLANT MATERIALS | BRITISH TECHNOLOGY GROUP LTD. (GB) | 1993-01-21 | — | — | WO | claimed |
| EP-0366770-A1 | LIPOSOMES COUPLED TO HORMONES. | SANDOZ AG (CH) | 1990-05-09 | — | — | EP | claimed |
| WO-1989011270-A1 | LIPOSOMES COUPLED TO HORMONES | SANDOZ AG (CH) | 1989-11-30 | — | — | WO | claimed |